BCLS Fund III Investments, LP 13D and 13G filings for Dianthus Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 07:54 am Sale |
2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH |
BCLS Fund III Investments, LP | 2,689,707 8.800% |
-302,321 (-10.10%) |
Filing |
| 2024-02-02 4:32 pm Purchase |
2024-01-24 | 13G | Dianthus Therapeutics, Inc. DNTH |
BCLS Fund III Investments, LP | 2,992,028 9.990% |
2,992,028 (New Position) |
Filing |